The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move to strengthen its wound care portfolio, Sonoma Pharmaceuticals (NASDAQ: SNOA) announced it received FDA 510(k) clearance to expand the indications and packaging options for its Microdacyn Wound Irrigation Solution. The clearance covers a broader range of wound types and introduces multi-use packaging, according to a company statement.
The approval comes as the global wound care market experiences rapid growth, with increasing demand for advanced irrigation solutions. The expanded clearance allows Sonoma to market the product in new segments, potentially boosting near-term revenue. SNOA closed at $1.23 on June 29, 2026, per market data.
Sign in to access this content
Sign InInvestors are monitoring sales developments following the approval, especially with no major corporate events on the calendar in the next two weeks. The market is also watching for any new distribution agreements or strategic partnerships that could expand Microdacyn's reach in U.S. markets. Technically, the stock traded between $1.13 and $1.27 in the last session, reflecting cautious anticipation.